RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells

Table 1 The 50 % inhibitory concentration (IC50) of cisplatin in A549 and A549/DDP cells 48 h after drug treatment

Cell	Control	siFANCF	siFANCL	siFANCF+	siFANCD2	siFANCD2+	siFANCD2+
Cell	Control	siFANCF	siFANCL	siFANCL		siFANCF	siFANCL
A549	4.97 ± 0.32	3.05 ± 0.24^a	2.46 ± 0.21^b	2.44 ± 0.27 ^b	2.48 ± 0.31 ^b	2.45 ± 0.18 ^b	2.40 ± 0.23 ^b
A549/DDP	34.15 ± 0.42	4.43 ± 0.28^c	2.51 ± 0.33^{c, d}	2.48 ± 0.25 ^{c, d}	2.54 ± 0.17 ^{c, d}	2.52 ± 0.22 ^{c, d}	2.47 ± 0.19 ^{c, d}
SK-MES-1	9.92 ± 0.35	3.47 ± 0.25^c	2.68 ± 0.29^c	2.45 ± 0.32^c	2.58 ± 0.23^c	2.50 ± 0.33^c	2.46 ± 0.35^c

^acompared with control, p = 0.009; ^bcompared with control, p = 0.001; ^ccompared with control, p < 0.001; ^dcompared with siFANCF, p < 0.001

ISSN: 1423-0127